www.investorideas.com defense stocks blog- Homeland Security news
Two men arrested and charged Monday were part of an al Qaeda-supported plot to derail a passenger train, the Royal Canadian Mounted Police said.
The suspects, Chiheb Esseghaier and Raed Jaser, are accused of conspiring to kill people on a VIA train, police said. Officials said that the suspects had the capacity to carry out an attack but that the public was never in imminent danger.
The two men were receiving support "in the form of direction and guidance" from al Qaeda elements in Iran, police said. They are not Canadian citizens.
Follow complete coverage of breaking news on CNN TV, http://cnn.com and CNN Mobile.
Published at (www.investorideas.com defense stocks blog ) Research defense and Homeland Security stocks with the largest global defense stocks directory online for investors at Investorideas.com and www.Homelanddefensestocks.com click here: http://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp Defense and security companies - Become a showcase defense stock at www.investorideas.com and www.homelanddefensestocks.com for as little as $1000 month
Monday, April 22, 2013
Thursday, April 18, 2013
Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
SAN DIEGO - April 18, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD),
disclosed that a poster presentation entitled: "Extracorporeal Exosome
Removal: A Therapeutic Strategy to Address an Evolutionary Survival
Mechanism Shared by Cancer and Infectious Viral Pathogens," is being
presented today at the International Society of Extracellular Vesicles
(ISEV) 2013 conference being held in Boston, MA. Dr. Annette Marleau,
Director of Tumor Immunology at Aethlon Medical will give the
presentation. Information related to ISEV 2013 can be accessed online
at: www.isevmeeting.org
The Aethlon presentation discusses the specificity of the Aethlon
Hemopurifier® to address evolved glycopathogen targets that are
instrumental in cancer and infectious disease progression. Significant
points addressed in the presentation include emerging knowledge of
exosome secretion, which is a notable feature of malignancy owing to the
diverse roles of these particles in tumor-mediated immune suppression,
angiogenesis, metastasis, and resistance to therapeutic agents. As
cancer-secreted exosomes remain a critical target not addressed by drug
therapies, the Company is expanding the potential utility of the
Hemopurifier® to include cancer. In this role, the Hemopurifier®
provides an adjuvant strategy to improve current and emerging cancer
treatment outcomes without adding drug toxicity. To date, pre-clinical
Hemopurifier® studies have validated the capture of exosomes underlying
breast cancer, metastatic melanoma, ovarian cancer, lymphoma, and
colorectal cancer.
The Aethlon Hemopurifier® consists of the lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of a plasma membrane device that is compatible for use with standard CRRT and dialysis units. GNA-based capture is mediated by unique high mannose signatures abundant on the surface of cancer-secreted exosomes as well as glycoproteins that reside on the outer membrane of infectious viral pathogens.
In human studies of treatment naive HIV and Hepatitis-C (HCV) infected individuals, Hemopurifier® therapy demonstrated average viral load reductions of greater than 50% during single four-hour treatment applications. A three-treatment Hemopurifier® protocol combined with interferon-based standard-of-care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. In this same clinical program, post-treatment elution studies documented the capture of up to 300 billion HCV copies by the Hemopurifier® during a single six-hour treatment. A human feasibility study to initiate HCV human studies in the United States is pending IDE approval by the U.S. Food and Drug Administration (FDA).
Based on human treatment experience and exosome capture validations, the Company has identified candidate research centers to conduct a Hemopurifier® therapy study in cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
The Aethlon Hemopurifier® consists of the lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of a plasma membrane device that is compatible for use with standard CRRT and dialysis units. GNA-based capture is mediated by unique high mannose signatures abundant on the surface of cancer-secreted exosomes as well as glycoproteins that reside on the outer membrane of infectious viral pathogens.
In human studies of treatment naive HIV and Hepatitis-C (HCV) infected individuals, Hemopurifier® therapy demonstrated average viral load reductions of greater than 50% during single four-hour treatment applications. A three-treatment Hemopurifier® protocol combined with interferon-based standard-of-care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. In this same clinical program, post-treatment elution studies documented the capture of up to 300 billion HCV copies by the Hemopurifier® during a single six-hour treatment. A human feasibility study to initiate HCV human studies in the United States is pending IDE approval by the U.S. Food and Drug Administration (FDA).
Based on human treatment experience and exosome capture validations, the Company has identified candidate research centers to conduct a Hemopurifier® therapy study in cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Wednesday, April 17, 2013
Homeland Security Stock, Homeland Security Corporation (OTC Markets: HSCC) Reports Alliance with Sense Technologies to Integrate Identification and Access Control Into Multiple Security Applications
WRIGHTWOOD, CA - April 16, 2013 (Investorideas.com newswire) Homeland Security Corporation (PINKSHEETS: HSCC)
reported earlier in March that the company has formed a joint venture
with Sense Technologies for the development, sale and support of
additional identification methods, including Biometrics and Access
control solutions to HSCC's existing product line. Sense Technologies is
a custom developer and solution provider of integrated hardware and
proprietary software targeting the Transportation, Pharmaceutical, Law
Enforcement, Healthcare, Travel and Tourism, Time and Attendance and
Access Control industries.
HSCC and Sense have formed an alliance to co-develop multiple
security applications using HSCC surveillance and CCTV technologies with
Biometric and access control solutions to positively identify all users
accessing the system. The venture will add the most important layer of
security which is to make sure an authorized individual is the one
accessing the system or in some cases a machine. Combined with the
products HSCC distributes and has developed, the result is a totally
secure system with a complete "Audit" trail from start to finish. Sense
website can be viewed at www.senseme.com.
The company plans to target existing and new clients and industries with newly developed systems. The Sense Frontend and Backend system has the ability to integrate with any biometric, including Iris, Face, Fingerprint, and Voice depending on the application required. The systems have been designed to positively identify an authorized user and grant access, allow entry or "dispense" a product based on the user's level of authorization or license.
"We are excited to partner with Sense to bring real life positive identification to our existing security solutions. This partnership will create a much needed 'Revenue Stream' and allow the company to enter and expand new markets with complete turnkey solutions," stated David Shade, CEO of Homeland Security Corporation.
About HSCC
Homeland Security Corporation - Security and Surveillance, Biometrics and Access Control Solutions, Legal, Regulatory compliance & Security Surveillance in Marijuana Markets
Homeland Security Corporation (OTC:HSCC.PK), is a leading innovator, consultant and implementer of advanced security driven technologies that can be deployed in any environment to meet a clients security or regulatory needs. The company has been in the security product and installation business since 2001. http://www.hscsurveillance.com/
Investor info and financials
http://www.homelandsecuritycorporation.com/investors/
Biometrics and Access Control Solutions
http://www.senseme.com/
SAFE HARBOR
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with statements regarding Homeland's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those anticipated.
Contact:
Homeland Security Corporation
David L. Shade
877-931-1999
Published at Investorideas.com Newswire
More info on HSCC at Investorideas.com Visit: http://www.investorideas.com/CO/HSCC/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. All investment involves risk and loss of investment. Disclosure: HSCC has compensated investorideas.com the equivalent of $ten thousand per month in 144 shares for publishing news and content. Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp HSCC is not a fully reporting company. More info can be viewed at otcmarkets.com and the company websites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
The company plans to target existing and new clients and industries with newly developed systems. The Sense Frontend and Backend system has the ability to integrate with any biometric, including Iris, Face, Fingerprint, and Voice depending on the application required. The systems have been designed to positively identify an authorized user and grant access, allow entry or "dispense" a product based on the user's level of authorization or license.
"We are excited to partner with Sense to bring real life positive identification to our existing security solutions. This partnership will create a much needed 'Revenue Stream' and allow the company to enter and expand new markets with complete turnkey solutions," stated David Shade, CEO of Homeland Security Corporation.
About HSCC
Homeland Security Corporation - Security and Surveillance, Biometrics and Access Control Solutions, Legal, Regulatory compliance & Security Surveillance in Marijuana Markets
Homeland Security Corporation (OTC:HSCC.PK), is a leading innovator, consultant and implementer of advanced security driven technologies that can be deployed in any environment to meet a clients security or regulatory needs. The company has been in the security product and installation business since 2001. http://www.hscsurveillance.com/
Investor info and financials
http://www.homelandsecuritycorporation.com/investors/
Biometrics and Access Control Solutions
http://www.senseme.com/
SAFE HARBOR
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with statements regarding Homeland's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those anticipated.
Contact:
Homeland Security Corporation
David L. Shade
877-931-1999
Published at Investorideas.com Newswire
More info on HSCC at Investorideas.com Visit: http://www.investorideas.com/CO/HSCC/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. All investment involves risk and loss of investment. Disclosure: HSCC has compensated investorideas.com the equivalent of $ten thousand per month in 144 shares for publishing news and content. Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp HSCC is not a fully reporting company. More info can be viewed at otcmarkets.com and the company websites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Biodefense Stock Alert; Aethlon Medical (OTCBB: AEMD) Moves Following News on Contract
Point Roberts, WA - April 17, 2013 (Investorideas.com newswire) -
Investorideas.com, an investor research portal specializing in sector
research for independent investors including biodefense and homeland
security stocks issues a trading alert for Aethlon Medical, Inc. (OTCBB: AEMD), trading at $0.1099, up 0.0070 6.80% 12:43PM EDT on over 688,000 shares. The stock had a morning high of $0.12.
The company reported yesterday it entered into a subcontract
agreement with Battelle Memorial Institute (Battelle) to provide
services underlying a $22.8 million prime contract that was recently
awarded to Battelle by the Defense Advanced Research Projects Agency
(DARPA).
According to the press release, "The objective of this contract program is to integrate component technologies developed in DARPA's Dialysis Like Therapeutics (DLT) program into medical device that would save military and civilian lives by effectively treating sepsis. Beyond expanding our opportunity in the DLT program, we are honored to have the opportunity to work with Battelle (the world's largest independent research and development organization) on this endeavor."
The Company's Chairman and CEO also went on to say, "I am pleased to report that the funding spigot for countermeasures against bioterror and pandemic threats has been turned back on. Last month, The Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2013 was signed into law by President Obama. The law reauthorizes provisions of the Project Bioshield Act of 2004 and extends the mandate of the Biomedical Advanced Research and Development Authority (BARDA) to support medical countermeasure development for biothreat agents for possible inclusion in the U.S. Strategic National Stockpile. PAHPRA also enhances the authority of the FDA to support rapid responses to public health emergencies by clarifying that even before an event occurs, FDA may issue an emergency use authorization to allow emergency use of certain products as medical countermeasures. The Congressional Budget Office estimates that $11 billion will be spent on PAHPRA between fiscal years 2014 to 2018."
Full news: http://finance.yahoo.com/news/aethlon-medical-aemd-note-government-133000119.html
More info on AEMD: http://www.investorideas.com/CO/AEMD/
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free news and stock alerts including biotech and biodefense stocks http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - biotech and life sciences, biodefense and homeland security , water, renewable energy, mining stocks http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: AEMD is a paid client for news release and content distribution on the investorideas.com newswire and syndication partners (annual fee program 9700)
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
According to the press release, "The objective of this contract program is to integrate component technologies developed in DARPA's Dialysis Like Therapeutics (DLT) program into medical device that would save military and civilian lives by effectively treating sepsis. Beyond expanding our opportunity in the DLT program, we are honored to have the opportunity to work with Battelle (the world's largest independent research and development organization) on this endeavor."
The Company's Chairman and CEO also went on to say, "I am pleased to report that the funding spigot for countermeasures against bioterror and pandemic threats has been turned back on. Last month, The Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2013 was signed into law by President Obama. The law reauthorizes provisions of the Project Bioshield Act of 2004 and extends the mandate of the Biomedical Advanced Research and Development Authority (BARDA) to support medical countermeasure development for biothreat agents for possible inclusion in the U.S. Strategic National Stockpile. PAHPRA also enhances the authority of the FDA to support rapid responses to public health emergencies by clarifying that even before an event occurs, FDA may issue an emergency use authorization to allow emergency use of certain products as medical countermeasures. The Congressional Budget Office estimates that $11 billion will be spent on PAHPRA between fiscal years 2014 to 2018."
Full news: http://finance.yahoo.com/news/aethlon-medical-aemd-note-government-133000119.html
More info on AEMD: http://www.investorideas.com/CO/AEMD/About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free news and stock alerts including biotech and biodefense stocks http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - biotech and life sciences, biodefense and homeland security , water, renewable energy, mining stocks http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: AEMD is a paid client for news release and content distribution on the investorideas.com newswire and syndication partners (annual fee program 9700)
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Monday, April 1, 2013
Homeland Security –Defense site for sale
Homeland Security –Defense site for sale
Investorideas.com has the following website for sale
National Homeland Security Knowledgebase.com
call 800 665 0411
or Dvanzant@investorideas..com
About InvestorIdeas.com: Investor Ideas for global investors; invest in what you like!
www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas in biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.
The Investor Ideas newswire is a news source on Google news, Google Currents and Linkedin.com/Today news. Investorideas.com newswire is now available as a free mobile app for iPhone orAndroid. Go here or here for link
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com News on Linkedin.com/today
Sign up for free stock alerts at Investorideas.com
Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in over 14 leading sectors
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com
Thursday, March 21, 2013
Q&A Interview with Scott Sacknoff of the SPADE Defense Index (NYSE: ^DXS) Discussing Sequestration and its impact on the Defense sector and Defense Stocks
Q&A Interview with Scott Sacknoff of the SPADE Defense Index (NYSE: ^DXS) Discussing Sequestration and its impact on the Defense sector and Defense Stocks
Point Roberts WA- March 11, 2013 (www.investorideas.com newswire, www.homelanddefensestocks.com ) Investorideas.com, an investor research portal specializing in sector research including defense and Homeland Defense stocks issues a recent interview with Mr. Scott Sacknoff of the SPADE Defense Index (NYSE: ^DXS), the underlying index for the Powershares Aerospace & Defense ETF (NYSE: PPA).
Scott Sacknoff discusses his impressions on the sequestration and its impact on the defense sector and defense stocks.
Q: Investorideas.com
Mr. Sacknoff, several months ago you mentioned that until the sequestration was resolved you planned to be pretty quiet, why is that?
A: Sacknoff: That’s true. Last year I said that until all the sequestration and budget issues were resolved, how defense stocks would response was just a guess. Calling a bottom without knowing where cuts were going to come from, which programs would be impacted, and as importantly, when they’d be impacted makes evaluating companies and stocks more difficult that normal. That said, there were a number of strengths in the sector – international exports, growth in commercial aerospace, cybersecurity, and great balance sheets with tremendous cash positions and I thought these factors would offset the flattening and declines in the defense budget. But sequestration was a wild card. Recognizing the stabilizing factors means little when the government throws a monkey wrench into your calculations. So instead of guessing, putting out an opinion didn’t seem right.
Q: Investorideas.com
So, sequestration took effect. Were you surprised that Congress didn’t fix the issue?
A: Sacknoff: Not really. I thought it was a horrible idea and its execution will cause lots of problems whose impact won’t be felt for months, but nothing Congress does (or doesn’t do) really surprises me anymore. Democrats thought he Republicans would budget and they called that bluff and decided enacting budget cuts were more important than supporting the defense sector.
Q: Investorideas.com
And what did happen in the market?
A: Sacknoff: Well, despite constant media attention on the fiscal cliff and sequestration the SPADE Defense Index (NYSE: DXS) managed to outperform the broader market, gaining 16.3% in 2012. And it’s up 5% more to start 2013, 52-week highs. So those that said, they will ride it out and collect the dividends, which for the Powershares Aerospace & Defense ETF was a bit above 2.0% according to Yahoo, they were happy they chose that path. Still, the market reaction instead of ignoring sequestration could have focused on the impact and drop in GDP and stocks could have easily have fallen. There was something else I did find unusual.
Q: Investorideas.com
What was that?
A: Sacknoff: Well, I believe that in an unknown environment, owning a fund for diversifications reasons instead of holding an individual stock makes sense; especially if you are unsure which companies would be impacted the most. Yet over the past several months, the opposite appears to have happened. As the stocks, and of course the funds, moved higher, so people were obviously buying the sector, the number of shares held in the various funds declined. It’s a shame because when you compare the performance of companies such as Lockheed Martin (NYSE: LMT) and Boeing (NYSE: BA) with the Powershares Aerospace & Defense ETF (NYSE: PPA) for example, and investors would have benefited from being invested in the fund.
Q: Investorideas.com
So, where do you think things are headed from here?
A: Sacknoff: There is still a fair amount of unknowns however some things to keep in mind. A Continuing Resolution to fund the government at 2012 levels through September is currently being debated. This would provide DoD with $518 billion in nonwar funding plus an additional $87 billion for overseas war-on-terror activities.
Now, many people outside Washington would think is a good thing, yet the problem with a CR is that not only do the budget numbers remain fixed but what their spent on is fixed as well. Picture if you budgeted $20,000 for a new car in 2012 and being told ‘here’s another $20,000 to spend for a car in 2013’ even though you didn’t need one and would rather spend the money on fixing your heating system. It does appear though that Congress will give the Pentagon some flexibility to allocate funds with some limited flexibility. Investors should keep in mind though that anticipated defense spending reductions over the next several years will take us, roughly, to the levels seen in 2007, levels much higher than after 9/11, near the beginning of the last defense spending build-up.
Also, sequestration reductions won’t mean the canceling of previously awarded contracts and the agency is going to find as many non-essential areas to cut as possible. The first cuts announced will be closing the military’s worldwide commissary network one extra day each week and issuing partial furloughs to 15,000 military school teachers and staff. So, for at least the moment, the impact on public defense stocks is delayed.
Q. Investorideas.com
Lastly, what do you think the play is for 2013?
A: Sacknoff: Personally, I’d expect aerospace suppliers to produce solid gains and for Boeing to rebound from 2012’s market underperformance once the issues with the 787 batteries are resolved. And I see C4ISR and cybersecurity firms gaining traction in spite of the budget issues at DoD as IT companies such as SAIC, CACI, KEYW, etc gain customers from other government agencies and increasingly from private firms wanting DoD-level security to protect their networks. With cyber attacks up 44% and 75 million pieces of malware on the net, even the banking community has turned to the National Security Agency for advice.
Investorideas.com
This has been great. Thank you for making the time to chat today.
Sacknoff: My pleasure.
InvestorIdeas.com is a meeting place for investors and public companies in leading sectors . Find investing ideas in biotech stocks, tech and mobile stocks, mining stocks , oil and gas , water stocks , renewable energy, beverage stocks, defense stocks, nanotech and more . The Investor Ideas newswire is a news source on Google news and Linkedin.com/Today news .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Or …
Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in over 14 leading sectors including defense stocks, oil and gas stocks, mining …
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products
http://www.investorideas.com/About/Disclaimer.asp
or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com
Point Roberts WA- March 11, 2013 (www.investorideas.com newswire, www.homelanddefensestocks.com ) Investorideas.com, an investor research portal specializing in sector research including defense and Homeland Defense stocks issues a recent interview with Mr. Scott Sacknoff of the SPADE Defense Index (NYSE: ^DXS), the underlying index for the Powershares Aerospace & Defense ETF (NYSE: PPA).
Scott Sacknoff discusses his impressions on the sequestration and its impact on the defense sector and defense stocks.
Q: Investorideas.com
Mr. Sacknoff, several months ago you mentioned that until the sequestration was resolved you planned to be pretty quiet, why is that?
A: Sacknoff: That’s true. Last year I said that until all the sequestration and budget issues were resolved, how defense stocks would response was just a guess. Calling a bottom without knowing where cuts were going to come from, which programs would be impacted, and as importantly, when they’d be impacted makes evaluating companies and stocks more difficult that normal. That said, there were a number of strengths in the sector – international exports, growth in commercial aerospace, cybersecurity, and great balance sheets with tremendous cash positions and I thought these factors would offset the flattening and declines in the defense budget. But sequestration was a wild card. Recognizing the stabilizing factors means little when the government throws a monkey wrench into your calculations. So instead of guessing, putting out an opinion didn’t seem right.
Q: Investorideas.com
So, sequestration took effect. Were you surprised that Congress didn’t fix the issue?
A: Sacknoff: Not really. I thought it was a horrible idea and its execution will cause lots of problems whose impact won’t be felt for months, but nothing Congress does (or doesn’t do) really surprises me anymore. Democrats thought he Republicans would budget and they called that bluff and decided enacting budget cuts were more important than supporting the defense sector.
Q: Investorideas.com
And what did happen in the market?
A: Sacknoff: Well, despite constant media attention on the fiscal cliff and sequestration the SPADE Defense Index (NYSE: DXS) managed to outperform the broader market, gaining 16.3% in 2012. And it’s up 5% more to start 2013, 52-week highs. So those that said, they will ride it out and collect the dividends, which for the Powershares Aerospace & Defense ETF was a bit above 2.0% according to Yahoo, they were happy they chose that path. Still, the market reaction instead of ignoring sequestration could have focused on the impact and drop in GDP and stocks could have easily have fallen. There was something else I did find unusual.
Q: Investorideas.com
What was that?
A: Sacknoff: Well, I believe that in an unknown environment, owning a fund for diversifications reasons instead of holding an individual stock makes sense; especially if you are unsure which companies would be impacted the most. Yet over the past several months, the opposite appears to have happened. As the stocks, and of course the funds, moved higher, so people were obviously buying the sector, the number of shares held in the various funds declined. It’s a shame because when you compare the performance of companies such as Lockheed Martin (NYSE: LMT) and Boeing (NYSE: BA) with the Powershares Aerospace & Defense ETF (NYSE: PPA) for example, and investors would have benefited from being invested in the fund.
Q: Investorideas.com
So, where do you think things are headed from here?
A: Sacknoff: There is still a fair amount of unknowns however some things to keep in mind. A Continuing Resolution to fund the government at 2012 levels through September is currently being debated. This would provide DoD with $518 billion in nonwar funding plus an additional $87 billion for overseas war-on-terror activities.
Now, many people outside Washington would think is a good thing, yet the problem with a CR is that not only do the budget numbers remain fixed but what their spent on is fixed as well. Picture if you budgeted $20,000 for a new car in 2012 and being told ‘here’s another $20,000 to spend for a car in 2013’ even though you didn’t need one and would rather spend the money on fixing your heating system. It does appear though that Congress will give the Pentagon some flexibility to allocate funds with some limited flexibility. Investors should keep in mind though that anticipated defense spending reductions over the next several years will take us, roughly, to the levels seen in 2007, levels much higher than after 9/11, near the beginning of the last defense spending build-up.
Also, sequestration reductions won’t mean the canceling of previously awarded contracts and the agency is going to find as many non-essential areas to cut as possible. The first cuts announced will be closing the military’s worldwide commissary network one extra day each week and issuing partial furloughs to 15,000 military school teachers and staff. So, for at least the moment, the impact on public defense stocks is delayed.
Q. Investorideas.com
Lastly, what do you think the play is for 2013?
A: Sacknoff: Personally, I’d expect aerospace suppliers to produce solid gains and for Boeing to rebound from 2012’s market underperformance once the issues with the 787 batteries are resolved. And I see C4ISR and cybersecurity firms gaining traction in spite of the budget issues at DoD as IT companies such as SAIC, CACI, KEYW, etc gain customers from other government agencies and increasingly from private firms wanting DoD-level security to protect their networks. With cyber attacks up 44% and 75 million pieces of malware on the net, even the banking community has turned to the National Security Agency for advice.
Investorideas.com
This has been great. Thank you for making the time to chat today.
Sacknoff: My pleasure.
InvestorIdeas.com is a meeting place for investors and public companies in leading sectors . Find investing ideas in biotech stocks, tech and mobile stocks, mining stocks , oil and gas , water stocks , renewable energy, beverage stocks, defense stocks, nanotech and more . The Investor Ideas newswire is a news source on Google news and Linkedin.com/Today news .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Or …
Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in over 14 leading sectors including defense stocks, oil and gas stocks, mining …
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products
http://www.investorideas.com/About/Disclaimer.asp
or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com
Wednesday, March 13, 2013
Defense and Security Investor Ideas: A year of sector stock research for just $67
March 13, 2013 (www.investorideas.com newswire)
www.InvestorIdeas.com, a global investor research portal for independent
investors, announces a special limited time offer on its annual
membership program, discounted from its previous price, to allow
investors that have missed the current market rally to invest and
research their favorite sector.
Members can login to access 14 global stock directories covering
water stocks, renewable energy stocks, oil and gas stocks, biotech
stocks, gold-mining stocks, nanotech stocks, Mobile stocks, Social
Networking and Cloud Computing Stocks, defense stocks, beverage stocks
and more! Directories include stocks on the TSX, OTC, PINK, NASDAQ,
Frankfurt, AIM, ASX, Hong Kong Exchange and major exchanges.
Investorideas.com stock directories are the most comprehensive online and are used by institutional investors as well as retail investors.
Directories are updated each month as new IPO's come to market in leading sectors.
From now until Friday investors can get the Investorideas.com annual membership for just $67 - discounted from its regular $97 price.
Directories are also sold individually in a clickable PDF format.
InvestorIdeas.com is a meeting place for investors and public companies in leading sectors . Find investing ideas in biotech stocks, tech and mobile stocks, mining stocks , oil and gas , water stocks , renewable energy, beverage stocks, defense stocks, nanotech and more . The Investor Ideas newswire is a news source on Google news and Linkedin.com/Today news .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products
http://www.investorideas.com/About/Disclaimer.asp
or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Investorideas.com stock directories are the most comprehensive online and are used by institutional investors as well as retail investors.
Directories are updated each month as new IPO's come to market in leading sectors.
From now until Friday investors can get the Investorideas.com annual membership for just $67 - discounted from its regular $97 price.
Directories are also sold individually in a clickable PDF format.
Join Investor Ideas - Become a Member for just $67
Expires 3:00 PM EST March 15th
http://www.investorideas.com/membership/On-Sale.asp
About InvestorIdeas.com:Expires 3:00 PM EST March 15th
http://www.investorideas.com/membership/On-Sale.asp
InvestorIdeas.com is a meeting place for investors and public companies in leading sectors . Find investing ideas in biotech stocks, tech and mobile stocks, mining stocks , oil and gas , water stocks , renewable energy, beverage stocks, defense stocks, nanotech and more . The Investor Ideas newswire is a news source on Google news and Linkedin.com/Today news .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products
http://www.investorideas.com/About/Disclaimer.asp
or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Subscribe to:
Posts (Atom)